Nanoparticles as carriers for growth hormone releasing factor

https://doi.org/10.1016/0168-3659(91)90098-XGet rights and content

Abstract

This study presents a useful approach for the identification of factors which must be considered to permit the development of successful nanoparticle growth hormone releasing factor (GRF) formulation. The results show that GRF can be associated with biodegradable poly(alkylcyanoacrylate) nanoparticles. Among other parameters, the moment at which GRF was incorporated in the polymerization medium was found to be a critical factor in avoiding the degradation of GRF and the covalent bonding of the peptide with the polymer. The drugpolymer interaction was, however, confirmed by gel permeation chromatography (GPC), showing the appearance of a heavier polymeric fraction when GRF was added at the very beginning of the polymerization process. Drug-release experiments suggested that the liberation of GRF from nanoparticles resulted rather from the bioerosion of the polymeric matrix than from the passive diffusion of the peptide through the polymer. Indeed, drug-release appeared dependent upon the esterase content of the incubation medium. Finally, it was found that the alkyl chain length of the cyanoacrylic polymer was able to modulate the rate of GRF release.

References (16)

There are more references available in the full text version of this article.

Cited by (71)

  • The delivery of drugs - peptides and proteins

    2019, Comprehensive Biotechnology
  • Advances on the formulation of proteins using nanotechnologies

    2017, Journal of Drug Delivery Science and Technology
    Citation Excerpt :

    Due to their rapid and easy polymerization, alkylcyanoacrylates have been the monomers of choice for this purpose [133,134]. Unfortunately, the potential reaction between the drug and the reactive monomers during the process constitutes a limitation of this approach [135]. Interfacial polymerization in oily core nanocapsules.

  • Mucoadhesive properties of low molecular weight chitosan- or glycol chitosan- and corresponding thiomer-coated poly(isobutylcyanoacrylate) core-shell nanoparticles

    2017, European Journal of Pharmaceutics and Biopharmaceutics
    Citation Excerpt :

    In these cases, inhibition of the P-gp generally enhances drug absorption as reported considering important anticancer agents such as Paclitaxel [19]. In previous studies, it has been shown that poly(alkylcyanoacrylate) (PACA) nanoparticles (NPs) are able to encapsulate peptides, proteins [20–23] and anticancer agents [19]. However, due to the hydrophobic character of PACA as well as to the negative charge of the surface of the corresponding NPs, their mucoadhesive potential is generally low and therefore they are of limited usefulness for transmucosal delivery.

  • The application of MALDI TOF MS in biopharmaceutical research

    2011, International Journal of Pharmaceutics
    Citation Excerpt :

    Thus, the formulation of small histidine-containing peptides, such as d-Lys6-GnRH, into PACA nanoparticles is an example for a pharmaceutical formulation with limited perspective to enter the biopharmaceutical market for human therapeutics. Polymer systems, including PACA nanoparticles, have also been deliberately conjugated to protein and peptide bioactives for reasons of enhanced entrapment efficiency (Liang et al., 2008), modified/sustained release characteristics (Grangier et al., 1991; Singh et al., 2007), targeted release (Pasut and Veronese, 2007), improved stability (Hillery et al., 1996; Pasut and Veronese, 2007), prolonged biological half lives (Pasut and Veronese, 2007) and enhanced absorption (Veronese and Harris, 2008). This approach, however, requires the site-specific functionalization of either protein/peptide or polymer in order to produce hybrid constructs with well-defined protein/peptide segments and well defined polymer chains (Gauthier and Klok, 2008).

  • The Delivery of Drugs - Peptides and Proteins

    2011, Comprehensive Biotechnology, Second Edition
  • Release and bioactivity of PACA nanoparticles containing D-Lys <sup>6</sup>-GnRH for brushtail possum fertility control

    2011, Journal of Controlled Release
    Citation Excerpt :

    Previously, we have demonstrated the covalent interference of some protein and peptide drugs, including D-Lys6-GnRH, during the polymerization process, which may explain the low release of bioactive observed in some studies [19,20]. The sustained release of bioactive via the bioerosion of the polymer material has previously been suggested for peptide copolymerized PACA nanoparticles in the presence of esterases and rat plasma [21]. Whether or not peptide released from copolymerized PACA nanoparticles is still bioactive has been investigated only in a few studies.

View all citing articles on Scopus
View full text